Inflammation and fibrosis in murine models of heart failure

L Bacmeister, M Schwarzl, S Warnke, B Stoffers… - Basic research in …, 2019 - Springer
Heart failure is a consequence of various cardiovascular diseases and associated with poor
prognosis. Despite progress in the treatment of heart failure in the past decades, prevalence …

Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications

M Ala, R Mohammad Jafari… - Fundamental & clinical …, 2021 - Wiley Online Library
Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First
of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in …

The complement C3-complement factor D-C3a receptor signalling axis regulates cardiac remodelling in right ventricular failure

S Ito, H Hashimoto, H Yamakawa, D Kusumoto… - Nature …, 2022 - nature.com
Failure of the right ventricle plays a critical role in any type of heart failure. However, the
mechanism remains unclear, and there is no specific therapy. Here, we show that the right …

Novel insights and new therapeutic potentials for macrophages in pulmonary hypertension

Y Zuo, B Li, M Gao, R Xiong, R He, N Li, Q Geng - Respiratory Research, 2024 - Springer
Inflammation and immune processes underlie pulmonary hypertension progression. Two
main different activated phenotypes of macrophages, classically activated M1 macrophages …

Exploring the Multifaceted Potential of Sildenafil in Medicine

C Pușcașu, A Zanfirescu, S Negreș, OC Șeremet - Medicina, 2023 - mdpi.com
Phosphodiesterase type 5 (PDE5) is pivotal in cellular signalling, regulating cyclic
guanosine monophosphate (cGMP) levels crucial for smooth muscle relaxation and …

Two birds with one stone: regular use of PDE5 inhibitors for treating male patients with erectile dysfunction and cardiovascular diseases

Z Cai, J Zhang, H Li - Cardiovascular Drugs and Therapy, 2019 - Springer
Patients with cardiovascular disease (CVD) frequently have erectile dysfunction (ED)
because the two conditions have similar risk factors and potential mechanisms. The …

Intravenous sildenafil for treatment of early pulmonary hypertension in preterm infants

L Schroeder, P Monno, B Strizek, T Dresbach… - Scientific Reports, 2023 - nature.com
Data is lacking on the effect of continuous intravenous sildenafil treatment in preterm infants
with early pulmonary hypertension (PH), especially in very low birth weight (VLBW) infants …

Ca2+/calmodulin-dependent protein kinase II is essential in hyperacute pressure overload

MJ Baier, S Klatt, KP Hammer, LS Maier… - Journal of molecular and …, 2020 - Elsevier
Abstract Background Activation of Ca 2+/calmodulin-dependent protein kinase II (CaMKII) is
established as a central intracellular trigger for various cardiac pathologies such as …

Can zaprinast and avanafil induce the levels of angiogenesis, bone morphogenic protein 2, 4 and 7 in kidney of ovariectomised rats?

Z Huyut, N Bakan, S Yıldırım, Hİ Akbay… - … of physiology and …, 2022 - Taylor & Francis
Objective This study investigated effects of zaprinast and avanafil on angiogenesis, vascular
endothelial growth factor (VEGF), bone morphogenic protein (BMP) 2, 4 and 7. Methods …

New possibilities in heart failure: the effects of tadalafil on diastolic function in patients undergoing robot-assisted radical prostatectomy

F Crocetto, V Cuomo, C Santoro, L Fiorillo, B Barone… - Applied Sciences, 2022 - mdpi.com
Inhibitors of phosphodiesterase type 5 (PDE5i) are the first-line treatment for erectile
dysfunction and are also used to treat pulmonary hypertension. PDE5i impedes the …